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Summary Cyclin Dl is a cell cycle regulator of G1 progression that has been suggested to play a relevant role in the pathogenesis of several
human cancer types. In the current study, the expression of cyclin Dl has been investigated in a series of 33 patients, with benign (10
patients), borderline (five patients) and malignant (18 patients) ovarian disease. Cyclin Dl protein and mRNA content were analysed by
Western blotting and reverse transcriptase polymerase chain reaction respectively. The levels of cyclin Dl protein were undetectable in
patients with benign disease, detectable in the majority of patients with borderline disease and elevated in those with ovarian carcinomas,
being significantly related to the degree of malignancy (carcinoma vs benign, P= 0.0001; benign vs borderline, P= 0.0238). A significant
relationship between cyclin Dl expression and tumour proliferative activity was also found (P= 0.000001). Moreover, eight benign lesions,
two borderline tumours and 11 carcinomas proved to be suitable for the analysis of cyclin Dl transcript, and emerging data demonstrated
significant agreement between protein abundance and mRNA expression. Results from the current study suggest that cyclin Dl expression
is associated with the degree of transformation and most probably plays a role in the early development of ovarian malignancy.
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Neoplastic cells are characterized by altered mechanisms of cell
growth and DNA replication. Recent advances in eukaryotic cell
cycle research have demonstrated the relevance of cell cycle
checkpoints (G,/S and G2/M transitions) in the control ofprogres-
sion along the proliferative cycle (Peeper et al, 1994). The GI/S
checkpoint is currently the best understood in mammalian cells; an
important group of molecules involved in this checkpoint control
has been identified in cyclins and their catalytic partners; these are
the so-called cyclin-dependent kinases (CDKs). Several studies
have reported that the abnormal expression ofcertain cyclins may
be associated with oncogenesis and cancer progression (Motokura
et al, 1993). To date, at least eight mammalian cyclin genes have
been identified (A, B, C, D 1-3, E, H) on the basis of their
different patterns of expression in the phases of the cell cycle
(Hunter and Pines, 1994). Among the members ofthe cyclin gene
family, cyclin Dl is the most strongly implicated in human tumori-
genesis (Hinds et al, 1994). Cyclin Dl is a GI-specific protein
essential for the progression through GU phase to S-phase (Baldin
et al, 1993); its expression and activity reach a peak in GI and
gradually decline in S-phase (Lukas et al, 1994). Cyclin DI associ-
ates with the CDK4 subunit to form a complex, activated by phos-
phorylation, that leads to the transition from G, phase into S-phase
(Pines, 1993). The cyclin DI locus has been mapped to the chro-
mosome 11 band q13, and amplifications of the 11q13 region, as
well as the cyclin Dl gene as a component of this amplicon, have
been observed in a variety of human carcinomas (Lammie and
Peters, 1991). The indication that the cyclin Dl gene is somehow
centrally relevant to cancer, functioning as an oncogene, is
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supported by several experimental observations (Jiang et al,
1993a; Lovec et al, 1994). Altered expression of cyclin Dl may
result from rearrangement, isolated as PRAD-1 in parathyroid
adenomas (Rosenberg et al, 1991), translocation, isolated as bcl-l
in B-lymphocytic malignancies (Motokura et al, 1991; Withers et
al, 1991), and amplification, such as in head and neck, breast and
squamous cell carcinomas (Lammie and Peters, 1991; Schuuring
et al, 1992).
Investigations on the cyclin Dl gene expression in human
ovarian tumours are lacking and, at present, no significant data are
available. The natural history and management of ovarian cancer
have been extensively studied and different prognostic indicators
have been identified (Perez et al, 1991). Biological factors, such as
DNA ploidy, cell kinetics and oncogene expression, have been
demonstrated to be extremely helpful in predicting tumour aggres-
siveness, clinical outcome and response to chemotherapeutic
agents. Among them, tumour proliferative activity, evaluated by
the thymidine labelling index (TLI), represents an important
prognostic factor able to estimate tumour aggressiveness and
chemosensitivity ofovarian neoplastic cells (Alama et al, 1994).
The aim of the current study is to investigate the expression of
cyclin Dl in human ovarian lesions and its relationship with trans-
formed phenotype and tumour kinetics.
MATERIALS AND METHODS
Patients and tumour samples
Thirty-three patients who presented at the Department of
Obstetrics and Gynecology ofthe University ofGenoaentered this
study from December 1994 to December 1995. Tissue samples
were obtained at the time ofprimary surgery. Specimens consisted
of 10 benign lesions, five borderline tumours and 18 ovarian carci-
nomas. Tumour histology is reported in Table 1. FIGO stage
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Table 1 Characteristics of patients, TLI and cyclin Dl expression in human
ovarian tumours
Patient Age (years) Histology TLI (%) Cyclin Dl expression
Protein mRNA
62
46
30
80
37
57
55
28
45
17
21
22
82
48
80
39
51
60
47
40
65
80
66
61
71
57
63
72
70
48
36
70
62
Thecoma
Dermoid
Dermoid
Mucinous
Endometrial
Cystoadenofibroma
Serous
Mucinous
Seromucinous
Serous
Me
Mucinous
Serous
Serous
Serous
Mucinous
Me
Serous
Serous
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Serous
Undifferentiated
Endometrioid
Endometrioid
Serous
Clear cell
Undifferentiated
Serous
Serous
Serous
Serous
Clear cell
Granulosa cell
Undifferentiated
Serous
Median: 0.20
0.20
0.01
0.01
0.40
0.30
0.01
0.20
0.20
0.20
0.01
gdian: 0.90
0.90
0.70
1.30
1.70
0.60
adian: 4.80
16.60
4.70
6.70
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8.50
0.90
0.40
1.10
0.20
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11.00
22.50
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14.50
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27.40
11.70
0.01
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ND, not determined; -, undetectable; +, detectable; ++, well detectable;
+++, highly detectable.
(Ulfelder et al, 1978) was available for 16 of the 18 malignant
tumours, and the group consisted of one stage I, one stage II, 11
stage III and three stage IV tumours. Data on histological grade,
available for 16 of these patients, identified two well-differenti-
ated, two moderately differentiated and 12 poorly differentiated
tumours. Adequate material from fresh ovarian tissues or ascites
were immediately processed for cyclin Dl expression and tumour
kinetic analyses.
Thymidine labelling index (TLI)
Cell kinetics, as the percentage ofthymidine-labelled tumour cells
in DNA synthesis, was evaluated in surgical samples or ascites.
Solid specimens were grossly mechanically disaggregated with
scissors and scalpel to obtain single-cell suspensions. Cells were
resuspended in RPMI 1640 medium (ICN) supplemented with
10% fetal calf serum (FCS, ICN) and labelled with 10 ,uCi ml-'
[3H]thymidine (specific activity 5 Ci mM-', Amersham) at 37'C
for 30 min. Radiolabelling was stopped with ice-cold phosphate-
buffered saline (PBS), and cells were cytocentrifuged onto slides
and fixed in methanol-acetic acid 3:1. Slides were then dipped in
NTB-2 Nuclear Track Emulsion (Kodak) and exposed at 4°C for
24 h; haematoxylin-eosin staining was performed after gold-acti-
vated autoradiography (Braunschweiger et al, 1976). Cells
containing more than five nuclear grains, over background, were
scored as labelled, and the proportion of labelled tumour cells
expressed as a percentage of the total cell population represents
the TLI value.
Western blot analysis
Cell suspensions were washed twice in cold PBS and dissolved in
lysis buffer (1% Triton X-100, 0.15 M sodium chloride, 10 mM
Tris, pH 7.4) containing protease inhibitors (50 ,ug ml-' phenyl-
methylsulphonyl fluoride, 2 jig ml-' aprotinin, 2 jig ml-' leupeptin)
at 4°C for 30 min. The protein concentration of cell lysates was
determined by the Bio-Rad Protein Assay kit using bovine serum
albumin (BSA) as a standard. Equal amounts of total proteins
(10 gg) were separated on a 12% polyacrylamide gel in the pres-
ence of sodium dodecyl sulphate (SDS) (SDS-PAGE). After run-
ning, gel was electrotransferred onto a nitrocellulose membrane
(Hybond C-Extra, Amersham). Filters were blocked with 5% BSA
(Sigma) in PBS at room temperature for 1 h. After washes in PBS-
T (0.05% Tween 20), blots were incubated with the cyclin DI
monoclonal antibody (Santa Cruz Biotechnology) at 1:1000 dilu-
tion in PBS-T at room temperature for 2 h. After three washes in
PBS-T, the filter was incubated with a 1:5000 dilution of horse-
radish peroxidase (HRP)-linked anti-mouse IgG secondary anti-
body (Dako) at room temperature for 1 h. After three washes, the
cyclin DI band (36 kDa) was visualized by chemiluminescent
detection (ECL, Amersham), following the supplier's recom-
mended procedures. Prestained low molecular weight markers
were used as reference.
Reverse transcriptase polymerase chain reaction
(RT-PCR) analysis
Specific cyclin DI transcript levels were determined by a semi-
quantitative RT-PCR amplification. Total RNA from fresh ovarian
samples was isolated using the RNAzol B method (Biotecx
Lab). Reverse transcription (RT) was carried out on 1 jig of total
RNA (at 42°C for 1 h) using the first-strand cDNA synthesis kit
(Clontech), according to the manufacturer's suggestions. RT was
inactivated by incubating the tubes at 94°C for 5 min. Synthetic
primers, to amplify specific mRNAs, were purchased from TIB-
MolBiol.
Cyclin Dl primers were: upstream, 5'-GGATGCTGGAG-
GTCTGCGAGGAAC-3'; downstream, 5'-GAGAGGAAGC-
GTGTGAGGCGGTAG-3'. ,B-actin primers were: upstream,
5'-GGCATCGTGATGGACTCCG-3'; downstream, 5'-GTCG-
GAAGGTGGACAGCGA-3'.
The co-amplification of the cyclin Dl and P-actin cDNAs was
carried out under the following conditions: 94°C for 1 min (denat-
uration), 65°C for 1.5 min (annealing), 72°C for 1.5 min (chain
extension) for30cycles, followedby afinal incubation at72°C for
15 min to flush-end the amplified fragments. Before the firstcycle,
tubes were soaked at94°C for 5 min. RT-PCR amplified fragments
(cyclin DI, 514 bp; P-actin, 600 bp) were analysed by 2% agarose
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. CancerResearch Campaign 1997Cyclin Dl expression in ovarian cancer 1265
gel electrophoresis and visualized by ethidium bromide staining.
Resulting bands were quantified and the relative amount of cyclin
Dl mRNA in each sample was estimated by normalization to the
P-actin mRNA detected in the same sample.
Densitometric analysis
Quantitative determination of the cyclin Dl protein and mRNA
bands were performed by scanning densitometry using an
Ultroscan XL densitometer (Pharmacia-LKB). The intensities of
the bands from radiographs were scanned and the resulting peak
areas, related to the absorbance, were determined.
The densitometric values were classed as undetectable (-;
< 0.001), detectable (+; median 0.061, range 0.020-0.076), well
detectable (++; median 0.347, range 0.209-0.696), highly
detectable (+++; median 1.471, range 0.887-2.260).
The association between cyclin Dl densitometric values and
tumour types was investigated using the Kruskal-Wallis statistic
and was tested for significance (P < 0.05).
The correlations between cyclin Dl densitometric scores and
TLI, as well as cyclin Dl protein and mRNA levels, were evalu-
ated using the Spearman rank test.
Statistical analyses were carried out using the Statistica 3.Ob
program from StatSoft.
RESULTS
Ten samples ofnon-malignant lesions, five borderline tumours and
18 carcinomas of the ovary were obtained at the time of primary
surgery. Table 1 outlines the histological types and the cyclin Dl
expression of the patients investigated. The most direct approach
to search for cyclin Dl abnormalities is to examine the protein
abundance; thus, cyclin Dl expression at the protein level was
evaluated by Western blotting analysis. Total cell lysates were
obtained from fresh solid tumours or ascites. To quantitate the
abundance of cyclin Dl, densitometric scanning of the 36-kDa
band was performed. The median densitometric value of cyclin
Dl for the benign group was markedly lower (0.001, range
0.001-0.387) than that of the borderline (0.209, range
0.001-0.348) and malignant group (0.388, range 0.027-2.260).
The analysis of the correlation between cyclin Dl densitometric
values and tumour types was performed by the Kruskal-Wallis
non-parametric test. As shown in Figure 1, comparison of the
groups indicates that the cyclin Dl protein content was signifi-
cantly higher in the carcinoma group than in the benign group (P =
0.0001) and higher in the borderline group than in the benign
group (P = 0.0238), but the difference did not reach statistical
significance when comparing the carcinoma group with the
borderline group (P = 0.0624). As cyclin Dl is related to the
proliferative status of the cells, a kinetic analysis of tumour
samples was carried out. A [3H]thymidine incorporation assay
(TLI) was used to estimate the percentage of tumour cells in DNA
synthesis. Benign lesions displayed lower TLI values (median TLI
0.20%, range 0.01-0.40) than borderline tumours (median TLI
0.90%, range 0.60-1.70) and carcinomas (median TLI 4.80%,
range 0.01-22.50). Furthermore, a significant association between
cyclin Dl expression and TLI, as assessed by the Spearman rank
test (r = 0.732, P = 0.000001) was found (Figure 2).
When adequate material could be obtained from fresh tumour
specimens, cyclin Dl mRNA levels were evaluated amplifying the
specific cyclin Dl fragment (514 bp) by RT-PCR analysis. This
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Figure 1 Cyclin Dl protein levels in ovarian tumours. Cyclin Dl values of
the 36 kDa band were obtained by densitometric scanning of Western
blotting as described in Materials and methods. Bars represent median
values. Comparison of groups (Kruskal-Wallis test): carcinoma vs benign
(P = 0.0001); benign vs borderline (P = 0.0238); carcinoma vs borderline
(P= 0.0624)
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Figure 2 Correlation between cyclin Dl expression and TLI in ovarian
tumours by the Spearman rank test. The levels of protein abundance are
significantly related to tumour proliferative activity
approach was feasible in 21 samples consisting of eight benign
tumours, two borderline tumours and 11 carcinomas. The levels of
cyclin Dl protein and mRNA, analysed by Western blotting and
RT-PCR respectively, were classed according to the signal intensi-
ties ofthe bands as follows: undetectable (-), detectable (+), easily
detectable (++) and highly detectable (+++). Representative
immunoblot and ethidium bromide-stained agarose gel are shown
in Figures 3 and 4.
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Figure 3 Expression of cyclin Dl protein in ovarian tumours by Western
blotting. Total cell lysates, balanced for protein loading, were separated by
12% SDS-PAGE, probed with the anti-cyclin Dl antibody and visualized
using the ECL method. Representative bands of different protein levels are
shown: lane 1, (+++) highly detectable; lane 2, (++) well detectable; lane 3,
(+) detectable; lane 4, (-) undetectable. The position of the cyclin Dl protein
(36 kDa) is reported on the left
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Figure 4 Expression of cyclin Dl mRNA in ovarian tumours by RT-PCR
amplification. Representative ethidium bromide-stained gel of cyclin Dl-
amplified fragments (514 bp) using primers as described in Materials and
methods. Lane 1, DNA molecular weight markers (bp); lane 2, (+++) highly
detectable; lane 3, (++) well detectable; lane 4, (+) detectable; lane 5, (-)
undetectable
As shown in Table 1, all the carcinomas exhibited detectable to
highly detectable cyclin Dl transcripts compared with the unde-
tectable signals ofthe benign lesions; in addition, cyclin Dl mRNA
expression coincided with or exceeded protein abundance, except in
three cases. A significant agreement between the two sets ofdata wvas
detenmined by Spearman statistical analysis (P = 0.0004), suggesting
that increased levels of cycin DI transcript and protein might be a
feature ofovarian malignancy in this preliminary series of21 patients.
In order to confirm that overexpression of cyclin Dl in ovarian
cancer cells was not only a consequence ofthe proliferative status
in malignant cells, cyclin Dl levels in exponential-growth cultures
were compared with those ofquiescent cells. Three ovarian cancer
cell lines, established from the ascites of three patients included
in the present study (patient nos. 16, 17 and 18 as in Table 1),
were used in a serum-starvation assay. These cell lines, named
OC 314 (patient no. 16), OC 315 (patient no. 17) and OC 316
(patient no. 18), have been extensively characterized as reported by
Alama et al (1996).
In addition, the MCF-7 breast cancer cell line, used as reference
for cyclin DI overexpression (Buckley et al, 1993), was also
included in the experiments. Cell cultures were either grown
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Figure 5 Expression of cyclin Dl mRNA in ovarian cancer cell lines by RT-
PCR amplification evaluated in serum-starved (3 days in RPMI medium
containing 1% FCS) and exponential (3 days in RPMI medium containing
10% FCS) cultures. Upper band, cyclin Dl (514 bp); lower band, f-actin
(600 bp). Lane 1, DNA molecular weight markers (bp); lane 2, no cDNA
(negative control); lanes 3, 5 and 7, OC 314, OC 315 and OC 316 (serum
starved); lanes 4, 6 and 8, OC 314, OC 315 and OC 316 (exponential);
lane 9, MCF-7 breast cancer cell line
36 kDa
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Figure 6 Cyclin Dl protein levels in ovarian cancer cell lines by Western
blotting evaluated in serum-starved (3 days in RPMI medium containing 1%
FCS) and exponential (3 days in RPMI medium containing 10% FCS)
cultures. Lanes 1, 3 and 5, OC 314, OC 315 and OC 316 (serum starved);
lanes 2, 4 and 6, OC 314, OC 315 and OC 316 (exponential); lane 7, MCF-7
breast cancer cell line. The position of the cyclin Dl protein (36 kDa) is
reported on the left
exponentially in 10% FCS or serum starved in 1% FCS for 3 days.
The cyclin Dl expression was assessed by RT-PCR and Western
blotting as reported in Figures 5 and 6; cell kinetics and densito-
metric results are summarized in Table 2. A marked decrease in
DNA synthesis was observed in all three cell lines after 3 days of
serum reduction. Collectively, the densitometric values of cyclin
DI obtained from mRNA and protein analyses were retained in the
range of the well detectable levels (++; range 0.209-0.696); the
mRNA expression remained constant in both starved and exponen-
tial cultures, while a slight protein content variability, probably
because of a different intracellular accumulation and/or degrada-
tion ofthe protein, was reported.
These data suggest that altered cyclin Dl overexpression could
be a relatively stable feature in malignant cells, at least in these
cultures, independent oftheir proliferative behaviour.
Table 2 Cyclin Dl expression and cell kinetic analysis in ovarian cancer cell lines
Cell line Serum starveda Exponentialb
TLI (%) mRNAc Protein TLI(%) mRNAc Protein
OC 314 8.9 0.457 0.314 55.0 0.476 0.599
OC 315 9.8 0.470 0.590 60.9 0.423 0.654
OC 316 11.6 0.487 0.568 62.8 0.480 0.299
aFor serum-starved cultures, the cells were grown to subconfluence in RPMI medium containing 10% FCS, the medium was replaced
with RPMI 1% FCS for 3 days. bFor exponential cultures, the cells were plated at 2 x 105 in 35-mm Petri dishes in RPMI medium
containing 10% FCS and grown for 3 days. cCyclin Dl mRNA was normalized to 1-actin mRNA values. The MCF-7 cyclin Dl -
overexpressing cell line densitometric values, used as reference, were 0.598 and 0.400 for mRNA and protein respectively.
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DISCUSSION
Various genetic alterations have been described in human ovarian
cancer, such as amplification of the oncogenes HER-2/neu, K-ras
and c-myc, as well as the mutation and overexpression of the p53
tumour-suppressor gene (Piver et al, 1991). Furthermore, chromo-
some aberrations, including translocations (Lee et al, 1990),
rearrangements (Pejovic et al, 1992) and aneuploidy (Rodenburg
et al, 1988), have also been reported. As a consequence, concur-
rent genomic abnormalities could result in alterations ofthe mech-
anisms controlling cellular replication at the molecular level,
leading to tumour promotion and progression. Although amplifica-
tion and overexpression of the cyclin D1 gene have been demon-
strated in various carcinomas (breast, urinary bladder, head and
neck, lung and oesophageal) and play a role in multistep carcino-
genesis, data concerning cyclin D1 expression in ovarian cancer
are presently lacking.
In the current paper, we reported that the malignant lesions
studied differed markedly from the benign lesions in their growth
behaviour; moreover, the proliferative activity in ovarian tumours
was positively related to the levels of cyclin DI protein, with Dl
being undetectable in benign lesions and highly expressed in carci-
nomas. Previous studies on cell proliferative activity and DNA
flow cytometry of ovarian cancer have demonstrated that highly
proliferating and aneuploid cancers are associated with tumour
aggressiveness and poor prognosis (Rodenburg et al, 1988; Alama
et al, 1994). Therefore, the concomitant analyses of a cell cycle-
related gene, such as cyclin Dl, with tumour kinetics might
provide additional insight into the biology and clinical aggressive-
ness ofthis disease.
The relationship between TLI and cyclin DI expression in the
33 patients with ovarian tumours in this study demonstrated that
higher TLI values were significantly associated with cyclin Dl
abundance in neoplastic cells, while lower proliferative activity
and undetectable cyclin Dl levels were observed in histologically
benign ovarian tissues.
The observation that expression of cyclin Dl is frequently
related to increased DNA synthesis is in agreement with data from
the literature reporting that G, cyclins are rate controlling for G1
duration and S progression. Indeed, overexpression of G, cyclins
in human fibroblasts 'in vitro' accelerated G, progression, short-
ening G, phase length and reducing serum requirement for the
transition from G, to S (Pagano et al, 1994). Similar results were
reported in a paper by Jiang et al (1993b) in which retrovirus-
transducted Rat 6 embryo fibroblasts, which stably overexpress
the human cyclin Dl cDNA, displayed abnormalities in cell cycle
and growth control, together with a decrease in the duration ofthe
G, phase which resulted in shortening their rates ofGI to S-phase
transition.
At the clinical level, some preliminary studies have shown that
cyclin Dl could represent a feature ofmalignancy with prognostic
significance. One of these reports showed that aberrant expression
of cyclin DI is involved in human hepatocarcinogenesis and, in a
subset of five patients with stage IV hepatocellular carcinomas
(HCCs), seemed to be associated with faster tumour growth and
aggressive behaviour than early-stage disease, for which no alter-
ations of the cyclin Dl gene were detected (Nishida et al, 1994).
Moreover, the prognostic significance of cyclin DI abnormalities
was investigated in squamous cell carcinomas ofthe head and neck
(HNSCC) in a study by Michalides et al (1995). The study showed
that cyclin Dl overexpression, detected by immunohistochemistry
in a retrospective series of 47 operable HNSCC, correlated with
rapid cancer recurrence and a poor survival. In addition, as no
correlations between cyclin Dl expression and other clinical
features (tumour size, stage) were reported, it was suggested that
cyclin D1 could represent an independent prognostic marker.
The pathogenetic relevance of cyclin Dl abundance in breast
cancer has also been described in detail. One of the first immuno-
histochemical studies (Bartkova et al, 1994) analysing the cyclin
Dl protein in human samples indicated significant differences in
the staining intensities between normal tissues and breast carci-
nomas; 37% of carcinomas revealed a marked detectable cyclin
Dl nuclear signal, while normal breast tissues were mainly nega-
tive. In addition, a more recent paper by Bartkova et al (1995),
including a larger number of tumours (breast, colorectal, uterine,
melanoma and soft tissue sarcoma) and their normal counterparts,
showed that cyclin Dl immunostaining in carcinomas ranged from
weak to high according to the degree of malignancy. The authors
concluded that alterations of cyclin Dl expression represented a
common feature ofmalignancy in different human cancers.
The present paper suggests that increased expression of cyclin
Dl and high percentage of S-phase cells might be related to the
degree of malignancy in ovarian cancer. However, such observa-
tions can not exclude that proliferative abnormalities might influ-
ence cyclin Dl expression in ovarian neoplastic cells. Although
further investigations are needed to precisely understand the role
of cyclin Dl in the mechanisms of tumorigenesis, the present
study could provide information on cyclin D1 expression as a
proliferation marker in benign and borderline ovarian lesions, thus
helping identify subsets of patients at increased risk of developing
ovarian carcinoma.
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